PBM’s control access for the branded pharmaceuticals. Removing drugs from their formulary can have a dramatic impact. Biosimilars will impact by reducing the cost by 20-30 percent or more. Interesting to see how express scripts controls costs rather than gaining rebates.
Read more here from BioPharmaDIVE:
